"Californians have legitimate concerns about access to affordable drugs, but SB 17 does not address them. It is a bad deal for business and does nothing to benefit patients."Read More

Small and innovative biopharmaceutical companies across California are currently investing in the life-saving treatments of tomorrow, creating well-paying jobs throughout the state and spurring economic growth.Read More